BTI
COGT icon

Blue Trust Inc’s Cogent Biosciences COGT Stock Holding History

Blue Trust Inc’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-117
Closed -$2K – 2348
2022
Q4 		$2K Buy
117
+40
+52% +$496 ﹤0.01% 1908
2022
Q3 		$1K Buy
77
+22
+40% +$302 ﹤0.01% 1898
2022
Q2 		$0 Buy
+55
New +$375 ﹤0.01% 1904

Other funds holding COGT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Blue Trust Inc's COGT Position: Q1 2023 in Review

Blue Trust Inc sold out of Cogent Biosciences (COGT) in Q1 2023, closing a stake of 117 shares — an estimated $2K sold.

Blue Trust Inc first reported a position in COGT in Q2 2022 and held it in 3 quarters. The position peaked at $2K in Q4 2022. 136 funds tracked by Wall St. Rank hold COGT as of Q1 2023.

  • Blue Trust Inc reported no remaining Cogent Biosciences position as of Q1 2023 after selling out during the quarter.
  • Blue Trust Inc sold 117 Cogent Biosciences shares in Q1 2023, an estimated $2K.
  • Blue Trust Inc first reported a position in Cogent Biosciences in Q2 2022 and held it in 3 quarters.
  • Blue Trust Inc's Cogent Biosciences position peaked at $2K in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2023.

Based on Blue Trust Inc's 13F filing for Q1 2023, filed 17 Apr 2023.